Mixed Results For China’s First Home-Grown COVID Antiviral

Russia Trial Meets Endpoints

 
• By Dexter Jie Yan
  
azvudine trial results
Genuine Biotech needs to submit complete Phase III data for azvudine within three years of conditional approval • Source: Shutterstock
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from China

More from Focus On Asia